Formerly knowly known as Creative BioMolecules, during 2000, Creative Biomolecules, Ontogeny, Inc. and Reprogenesis, Inc. merged to form Curis, Inc. The new Company's core technologies are based on its understanding of the role that morphogenic proteins play in human biology. These proteins are involved in the initiation and regulation of the cellular events responsible for the formation of human tissues and organs. The Company has product candidates in development for several applications including orthopaedic and dental reconstruction, treatment of kidney disease, and treatment of stroke and other neurological disorders. Through its efforts to patent and license its technology, the Company has a strong intellectual property position covering morphogenic proteins as therapies. The Company's lead product candidate, the OP-1 bone graft device, is in the final stages of development and commercialization.